Cedilla Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
Based in Cambridge, Massachusetts, Cedilla Therapeutics operates in biotechnology research with a focus on oncology. It is advancing approaches that look beyond traditional protein sequence and structure to consider how proteins function within cells. The company develops small-molecule agents that selectively and conditionally modulate proteins in their functional state to inhibit cancer-driving targets, pursuing precision oncology. Its programs include inhibitors aimed at TEAD and CDK2, targeting cancer by interfering with these critical cellular drivers. In 2024, Cedilla Therapeutics announced a collaboration with Bayer AG to develop and commercialize inhibitors targeting the CyclinE1/CDK2 complex.